GENRX LINEZOLID linezolid 600 mg tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

linezolid, Quantity: 600 mg

Disponível em:

Arrotex Pharmaceuticals Pty Ltd

DCI (Denominação Comum Internacional):

Linezolid

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: magnesium stearate; hypromellose; macrogol 8000; crospovidone; methylcellulose; titanium dioxide; hyprolose; silicon dioxide

Via de administração:

Oral

Unidades em pacote:

10

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Linezolid (intravenous or oral) is indicated for the treatment of suspected or proven infections due to Gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant Staphylococcus species and vancomycin resistant Enterococcus species. It is active against Gram-positive bacteria only and has no clinical activity against Gram-negative pathogens. Specific Gram-negative therapy is required if a concomitant Gram-negative pathogen is documented or suspected.

Resumo do produto:

Visual Identification: White coloured, oval shaped, biconvex, film-coated tablet with "APO" engraved on one side and "LIN600" on the other side.; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status de autorização:

Licence status A

Data de autorização:

2014-01-31